Review



ifn λ3 il 28b  (R&D Systems)


Bioz Verified Symbol R&D Systems is a verified supplier
Bioz Manufacturer Symbol R&D Systems manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    R&D Systems ifn λ3 il 28b
    Ifn λ3 Il 28b, supplied by R&D Systems, used in various techniques. Bioz Stars score: 93/100, based on 5 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+lambda+elisa+kit/Human+IL-28B%2FIFN-lambda+3+Quantikine+ELISA+Kit/pm39097965-66-52-54
    Average 93 stars, based on 5 article reviews
    ifn λ3 il 28b - by Bioz Stars, 2026-11
    93/100 stars

    Images

    Related Articles

    Centrifugation:

    Article Title: Expressions of type I-III interferons in Sjögren's syndrome and non-Sjögren's dry eye.
    Article Snippet: .. The sera was obtained after centrifugation (2000 × g for 10 min) of venous blood and stored until measurement with commercially available ELISA kits specific for IFN-α (BMS216, Affymetrix eBioscience), IFN-β (CSB-E09889h, Cusabi, Wuhan, China), IFN-γ (ab174443, Abcam, Cambridge, UK), IFN-λ1/IL-29 (DY7246, R&D Systems, Minneapolis, MN, USA), IFN-λ2/IL-28A (DY1587, R&D Systems), and IFN-λ3/IL-28B (D28B00, R&D Systems) according to the manufacturer’s instructions. ..

    Enzyme-linked Immunosorbent Assay:

    Article Title: Expressions of type I-III interferons in Sjögren's syndrome and non-Sjögren's dry eye.
    Article Snippet: .. The sera was obtained after centrifugation (2000 × g for 10 min) of venous blood and stored until measurement with commercially available ELISA kits specific for IFN-α (BMS216, Affymetrix eBioscience), IFN-β (CSB-E09889h, Cusabi, Wuhan, China), IFN-γ (ab174443, Abcam, Cambridge, UK), IFN-λ1/IL-29 (DY7246, R&D Systems, Minneapolis, MN, USA), IFN-λ2/IL-28A (DY1587, R&D Systems), and IFN-λ3/IL-28B (D28B00, R&D Systems) according to the manufacturer’s instructions. ..

    Article Title: Clostridium butyricum-induced ω-3 fatty acid 18-HEPE elicits anti-influenza virus pneumonia effects through interferon-λ upregulation.
    Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies IL-28A/IFN-lambda 2 anti-Mouse Monoclonal Ab (625,616) RSD MAB4635; RRID: AB_10718823 IL-28B/IFN-lambda 3 anti-mouse Monoclonal Ab (244,710) RSD MAB1789; RRID: AB_2233689 FITC-labeled anti-CD4 Ab (RM4-5) BD Biosciences 561,835; RRID: AB_394582 Per-CP-labeled anti-CD3 Ab (145-2C11) BD Biosciences 561,089; RRID: AB_394599 PE-labeled anti-CD8 Ab (53–6.7) BD Biosciences 561,095; RRID: AB_394571 Rat IgG2b Isotype Control antibody (LTF-2) Thermo Fisher Scientific 02-9288; RRID: AB_2532966 APC-labeled anti-CD326 (Ep-CAM) Ab (G8.8) Biolegend 118,213; RRID: AB_1134105 PB-labeled anti-CD45 Ab (30-F11) Biolegend 103,128; RRID: AB_493715 FITC-labeled anti-CD11c Ab (N418) Biolegend 117,305; RRID: AB_313774 PerCP anti-I-A/I-E (MHC II) Ab (M5/114.15.2) Biolegend 107,623; RRID: AB_893586 Bacterial and viral strains Bacterium: Clostridium butyricum MIYAIRI 588 MIYARISAN Pharmaceutical Co. N/A Virus: Influenza virus (A/Aichi/2/68) (H3N2) Yoshihiro Kawaoka N/A Chemicals, peptides, and recombinant proteins Penicillin-Streptomycin-Amphotericin B Suspension (1003) Wako 161-23181 MEM (103) gibco 11430-030 MEM Amino Acids (503) gibco 11130-051 MEM Vitamin Solution (1003) gibco 11120-052 Distilled water gibco 15230204 Newborn Calf Serum, heat inactivated gibco 26010066 0.25% Trypsin (13) gibco 15050065 Sodium bicarbonate solution (7.5% NaHCO3) Sigma S8761-100mL BSA Solution (7.5%) Sigma A8412-100ML L-Glutamine Solution (50x) Sigma G7513-100ML 0.5%-Trypan Blue Stain Solution Nacalai tesque 29853-34 Crystal Violet Nacalai tesque 09803-62 F-12K Medium ATCC ATCC 30-2004 Collagenase, type IV Worthington Collagenase LS004209 Recombinant DNase I (RNase-free) Takara 2270A RPMI 1640 Thermo Fisher Scientific 11875-085 HBSS Thermo Fisher Scientific 14025-76 EDTA Sigma E5134-50g Percoll GE Healthcare 17-0891-02 Formalin solution neutral buffered, 10% SIGMA HT501128-4L USDA-Grade Certified Fatal Bovine Serum [FBS] Cosmo bio 04-001-1A Isoflurane Pfizer 114-133403 (±)18-HEPE CAY 32840 AH7614 CAY 17713 GW1100 CEM CS-0280 Ionomycin Sigma I9657 Myristic acid Sigma M312 (Continued on next page) Cell Reports 41, 111755, December 13, 2022 e1 .. REAGENT or RESOURCE SOURCE IDENTIFIER Linoleic acid Sigma L1376 Oleic acid Sigma O1008 TUG-891 CAY 17035 FITC-dextran Sigma FD4-1G Critical commercial assays NucleoSpin RNA (Total RNA isolation Kit) MACHEREY-NAGEL 740955.50 Fixation/Permeablization Kit BD Biosciences 554714 High-Capacity RNA-to-cDNA Kit Thermo Fisher Scientific 4387406 SYBAR Green PCR Master Mix Thermo Fisher Scientific A25742 VeriKineTM Mouse IFN-a detection ELISA Kit PBL 42120-1 Mouse IFN-b Quantikine ELISA Kit RSD MIFNB0 LEGEND MAXTM Mouse IFN-g ELISA Kit Biolegend 430807 Mouse IL-28 ELISA Kit abcam ab100708 LEGEND MAXTM Mouse IL-6 ELISA Kit Biolegend 431307 LEGEND MAXTM Mouse TNF-a ELISA Kit Biolegend 430907 Human IL-29 (IFN-l1) ELISA Kit Biolegend 446307 Human IL-28A (IFN-l2) ELISA Kit RayBiotech ELH-IL28A-1 Human IL-28B/IFN-lambda 3 Quantikine ELISA Kit R&D Systems D28B00 Human Free Fatty Acid Receptor 4 (FFAR4) ELISA Kit CLOUD-CLONE SEG697HU Deposited data LC-MS/MS data MetaboLights https://www.ebi.ac.uk/metabolights/ reviewer18cf2487-8bc9-4b84-b575314f8fc149d5 Experimental models: Organisms/strains Mouse: BALB/c Charles River Laboratories Japan, Inc. N/A Mouse: C57BL/6J Charles River Laboratories Japan, Inc. N/A Mouse: Irf1 / mice The Jackson Laboratory JAX 002762 Mouse: Irf7 / mice The RIKEN BioResource Research Center RBRC01420 Human wild-type A549 cell line abcam ab255450 Human IRF-1 knockout A549 cell line abcam ab267042 Human IRF-7 knockout A549 cell line abcam ab267210 MDCK cell line Yoshihiro Kawaoka、 N/A Oligonucleotides See Table S1 for primers N/A N/A Software and algorithms Prism v9.0 GraphPad Software https://www.graphpad.com/scientific- software/prism/ FlowJo v10.07 TreeStar Inc https://www.flowjo.com/ Xcalibur 4.1 Thermo Fisher Scientific https://www.thermofisher.com/jp/ja/home/ industrial/mass-spectrometry/liquidchromatography-mass-spectrometrylc-ms/lc-ms-software/lc-ms-dataacquisition-software/xcalibur-dataacquisition-interpretation-software.html (Continued on next page) e2 Cell Reports 41, 111755, December 13, 2022 .. REAGENT or RESOURCE SOURCE IDENTIFIER Compound Discoverer3.1.1.12 Thermo Fisher Scientific https://www.thermofisher.com/jp/ja/ home/industrial/mass-spectrometry/ liquid-chromatography-massspectrometry-lc-ms/lc-ms-software/ multi-omics-data-analysis/compounddiscoverer-software.html Other TissueLyser II QIAGEN 85300 Stainless beads, 3mm TAITEC 0068218-000 100-mm cell strainer PLS 43-50100-03 FACSCantTM II BD Biosciences N/A Step One Plus (Real-time PCR system) Thermo Fisher Scientific N/A Liquid chromatography-tandem mass spectrometry (LC-MS/MS) Thermo Fisher Scientific N/A FACSCantTM II BD Biosciences N/A Freeze dryer EYELA FDU-2200 Centrifugal evaporator EYELA CVE-3110 Cooling trap device EYELA UT-2000 Diaphragm vacuum pomp EYELA NVP-2100 Vacuum pomp EYELA GCD-136XN Ball mill Retsxh MM 400 Zirconia ball NIKKATO CORPORATION YTZ-0.3 Centrifuge HITACHI CF16RN Vortex mixer Scientific Industries SI-0286 Methanol FUJIFILM Wako Pure Corporation 134-14523 Acetonitrile FUJIFILM Wako Pure Corporation 018-19853 BD Microtainer SST Tubes BD Biosciences 365967 SpectraMax iD5 Molecular Devices N/A

    Article Title: TRIM29 controls enteric RNA virus-induced intestinal inflammation by targeting NLRP6 and NLRP9b signaling pathways
    Article Snippet: Lentiviral vectors for shRNA were from Dharmacon Inc. (Horizon Discovery Group company): human TRIM29 (clone TRCN0000016352). .. The human IFN-lambda 3 (IFN-λ3, D28B00), mouse IFN-lambda 3 (IFN-λ3, DIY1789B-05), human IL-18 (DY318–05) and mouse IL-18 (DY7625–05) ELISA kits were from R&D Systems. .. RNeasy Mini Kit (250, 74106) and QIAprep Spin Miniprep Kit (250, 27106) were from QIAGEN.

    Article Title: TNF-related apoptosis-inducing ligand (TRAIL) exerts therapeutic efficacy for the treatment of pneumococcal pneumonia in mice.
    Article Snippet: .. Cytokine concentrations in BAL fluids of S. pneumoniae–infected mice were determined using DuoSet ELISA kits for IL6, KC, and TNF, and Quantikine ELISA kit for IFN (R&D Systems). .. TRAIL ELISA kit was purchased from Cusabio.

    Isolation:

    Article Title: Clostridium butyricum-induced ω-3 fatty acid 18-HEPE elicits anti-influenza virus pneumonia effects through interferon-λ upregulation.
    Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies IL-28A/IFN-lambda 2 anti-Mouse Monoclonal Ab (625,616) RSD MAB4635; RRID: AB_10718823 IL-28B/IFN-lambda 3 anti-mouse Monoclonal Ab (244,710) RSD MAB1789; RRID: AB_2233689 FITC-labeled anti-CD4 Ab (RM4-5) BD Biosciences 561,835; RRID: AB_394582 Per-CP-labeled anti-CD3 Ab (145-2C11) BD Biosciences 561,089; RRID: AB_394599 PE-labeled anti-CD8 Ab (53–6.7) BD Biosciences 561,095; RRID: AB_394571 Rat IgG2b Isotype Control antibody (LTF-2) Thermo Fisher Scientific 02-9288; RRID: AB_2532966 APC-labeled anti-CD326 (Ep-CAM) Ab (G8.8) Biolegend 118,213; RRID: AB_1134105 PB-labeled anti-CD45 Ab (30-F11) Biolegend 103,128; RRID: AB_493715 FITC-labeled anti-CD11c Ab (N418) Biolegend 117,305; RRID: AB_313774 PerCP anti-I-A/I-E (MHC II) Ab (M5/114.15.2) Biolegend 107,623; RRID: AB_893586 Bacterial and viral strains Bacterium: Clostridium butyricum MIYAIRI 588 MIYARISAN Pharmaceutical Co. N/A Virus: Influenza virus (A/Aichi/2/68) (H3N2) Yoshihiro Kawaoka N/A Chemicals, peptides, and recombinant proteins Penicillin-Streptomycin-Amphotericin B Suspension (1003) Wako 161-23181 MEM (103) gibco 11430-030 MEM Amino Acids (503) gibco 11130-051 MEM Vitamin Solution (1003) gibco 11120-052 Distilled water gibco 15230204 Newborn Calf Serum, heat inactivated gibco 26010066 0.25% Trypsin (13) gibco 15050065 Sodium bicarbonate solution (7.5% NaHCO3) Sigma S8761-100mL BSA Solution (7.5%) Sigma A8412-100ML L-Glutamine Solution (50x) Sigma G7513-100ML 0.5%-Trypan Blue Stain Solution Nacalai tesque 29853-34 Crystal Violet Nacalai tesque 09803-62 F-12K Medium ATCC ATCC 30-2004 Collagenase, type IV Worthington Collagenase LS004209 Recombinant DNase I (RNase-free) Takara 2270A RPMI 1640 Thermo Fisher Scientific 11875-085 HBSS Thermo Fisher Scientific 14025-76 EDTA Sigma E5134-50g Percoll GE Healthcare 17-0891-02 Formalin solution neutral buffered, 10% SIGMA HT501128-4L USDA-Grade Certified Fatal Bovine Serum [FBS] Cosmo bio 04-001-1A Isoflurane Pfizer 114-133403 (±)18-HEPE CAY 32840 AH7614 CAY 17713 GW1100 CEM CS-0280 Ionomycin Sigma I9657 Myristic acid Sigma M312 (Continued on next page) Cell Reports 41, 111755, December 13, 2022 e1 .. REAGENT or RESOURCE SOURCE IDENTIFIER Linoleic acid Sigma L1376 Oleic acid Sigma O1008 TUG-891 CAY 17035 FITC-dextran Sigma FD4-1G Critical commercial assays NucleoSpin RNA (Total RNA isolation Kit) MACHEREY-NAGEL 740955.50 Fixation/Permeablization Kit BD Biosciences 554714 High-Capacity RNA-to-cDNA Kit Thermo Fisher Scientific 4387406 SYBAR Green PCR Master Mix Thermo Fisher Scientific A25742 VeriKineTM Mouse IFN-a detection ELISA Kit PBL 42120-1 Mouse IFN-b Quantikine ELISA Kit RSD MIFNB0 LEGEND MAXTM Mouse IFN-g ELISA Kit Biolegend 430807 Mouse IL-28 ELISA Kit abcam ab100708 LEGEND MAXTM Mouse IL-6 ELISA Kit Biolegend 431307 LEGEND MAXTM Mouse TNF-a ELISA Kit Biolegend 430907 Human IL-29 (IFN-l1) ELISA Kit Biolegend 446307 Human IL-28A (IFN-l2) ELISA Kit RayBiotech ELH-IL28A-1 Human IL-28B/IFN-lambda 3 Quantikine ELISA Kit R&D Systems D28B00 Human Free Fatty Acid Receptor 4 (FFAR4) ELISA Kit CLOUD-CLONE SEG697HU Deposited data LC-MS/MS data MetaboLights https://www.ebi.ac.uk/metabolights/ reviewer18cf2487-8bc9-4b84-b575314f8fc149d5 Experimental models: Organisms/strains Mouse: BALB/c Charles River Laboratories Japan, Inc. N/A Mouse: C57BL/6J Charles River Laboratories Japan, Inc. N/A Mouse: Irf1 / mice The Jackson Laboratory JAX 002762 Mouse: Irf7 / mice The RIKEN BioResource Research Center RBRC01420 Human wild-type A549 cell line abcam ab255450 Human IRF-1 knockout A549 cell line abcam ab267042 Human IRF-7 knockout A549 cell line abcam ab267210 MDCK cell line Yoshihiro Kawaoka、 N/A Oligonucleotides See Table S1 for primers N/A N/A Software and algorithms Prism v9.0 GraphPad Software https://www.graphpad.com/scientific- software/prism/ FlowJo v10.07 TreeStar Inc https://www.flowjo.com/ Xcalibur 4.1 Thermo Fisher Scientific https://www.thermofisher.com/jp/ja/home/ industrial/mass-spectrometry/liquidchromatography-mass-spectrometrylc-ms/lc-ms-software/lc-ms-dataacquisition-software/xcalibur-dataacquisition-interpretation-software.html (Continued on next page) e2 Cell Reports 41, 111755, December 13, 2022 .. REAGENT or RESOURCE SOURCE IDENTIFIER Compound Discoverer3.1.1.12 Thermo Fisher Scientific https://www.thermofisher.com/jp/ja/ home/industrial/mass-spectrometry/ liquid-chromatography-massspectrometry-lc-ms/lc-ms-software/ multi-omics-data-analysis/compounddiscoverer-software.html Other TissueLyser II QIAGEN 85300 Stainless beads, 3mm TAITEC 0068218-000 100-mm cell strainer PLS 43-50100-03 FACSCantTM II BD Biosciences N/A Step One Plus (Real-time PCR system) Thermo Fisher Scientific N/A Liquid chromatography-tandem mass spectrometry (LC-MS/MS) Thermo Fisher Scientific N/A FACSCantTM II BD Biosciences N/A Freeze dryer EYELA FDU-2200 Centrifugal evaporator EYELA CVE-3110 Cooling trap device EYELA UT-2000 Diaphragm vacuum pomp EYELA NVP-2100 Vacuum pomp EYELA GCD-136XN Ball mill Retsxh MM 400 Zirconia ball NIKKATO CORPORATION YTZ-0.3 Centrifuge HITACHI CF16RN Vortex mixer Scientific Industries SI-0286 Methanol FUJIFILM Wako Pure Corporation 134-14523 Acetonitrile FUJIFILM Wako Pure Corporation 018-19853 BD Microtainer SST Tubes BD Biosciences 365967 SpectraMax iD5 Molecular Devices N/A

    Polymerase Chain Reaction:

    Article Title: Clostridium butyricum-induced ω-3 fatty acid 18-HEPE elicits anti-influenza virus pneumonia effects through interferon-λ upregulation.
    Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies IL-28A/IFN-lambda 2 anti-Mouse Monoclonal Ab (625,616) RSD MAB4635; RRID: AB_10718823 IL-28B/IFN-lambda 3 anti-mouse Monoclonal Ab (244,710) RSD MAB1789; RRID: AB_2233689 FITC-labeled anti-CD4 Ab (RM4-5) BD Biosciences 561,835; RRID: AB_394582 Per-CP-labeled anti-CD3 Ab (145-2C11) BD Biosciences 561,089; RRID: AB_394599 PE-labeled anti-CD8 Ab (53–6.7) BD Biosciences 561,095; RRID: AB_394571 Rat IgG2b Isotype Control antibody (LTF-2) Thermo Fisher Scientific 02-9288; RRID: AB_2532966 APC-labeled anti-CD326 (Ep-CAM) Ab (G8.8) Biolegend 118,213; RRID: AB_1134105 PB-labeled anti-CD45 Ab (30-F11) Biolegend 103,128; RRID: AB_493715 FITC-labeled anti-CD11c Ab (N418) Biolegend 117,305; RRID: AB_313774 PerCP anti-I-A/I-E (MHC II) Ab (M5/114.15.2) Biolegend 107,623; RRID: AB_893586 Bacterial and viral strains Bacterium: Clostridium butyricum MIYAIRI 588 MIYARISAN Pharmaceutical Co. N/A Virus: Influenza virus (A/Aichi/2/68) (H3N2) Yoshihiro Kawaoka N/A Chemicals, peptides, and recombinant proteins Penicillin-Streptomycin-Amphotericin B Suspension (1003) Wako 161-23181 MEM (103) gibco 11430-030 MEM Amino Acids (503) gibco 11130-051 MEM Vitamin Solution (1003) gibco 11120-052 Distilled water gibco 15230204 Newborn Calf Serum, heat inactivated gibco 26010066 0.25% Trypsin (13) gibco 15050065 Sodium bicarbonate solution (7.5% NaHCO3) Sigma S8761-100mL BSA Solution (7.5%) Sigma A8412-100ML L-Glutamine Solution (50x) Sigma G7513-100ML 0.5%-Trypan Blue Stain Solution Nacalai tesque 29853-34 Crystal Violet Nacalai tesque 09803-62 F-12K Medium ATCC ATCC 30-2004 Collagenase, type IV Worthington Collagenase LS004209 Recombinant DNase I (RNase-free) Takara 2270A RPMI 1640 Thermo Fisher Scientific 11875-085 HBSS Thermo Fisher Scientific 14025-76 EDTA Sigma E5134-50g Percoll GE Healthcare 17-0891-02 Formalin solution neutral buffered, 10% SIGMA HT501128-4L USDA-Grade Certified Fatal Bovine Serum [FBS] Cosmo bio 04-001-1A Isoflurane Pfizer 114-133403 (±)18-HEPE CAY 32840 AH7614 CAY 17713 GW1100 CEM CS-0280 Ionomycin Sigma I9657 Myristic acid Sigma M312 (Continued on next page) Cell Reports 41, 111755, December 13, 2022 e1 .. REAGENT or RESOURCE SOURCE IDENTIFIER Linoleic acid Sigma L1376 Oleic acid Sigma O1008 TUG-891 CAY 17035 FITC-dextran Sigma FD4-1G Critical commercial assays NucleoSpin RNA (Total RNA isolation Kit) MACHEREY-NAGEL 740955.50 Fixation/Permeablization Kit BD Biosciences 554714 High-Capacity RNA-to-cDNA Kit Thermo Fisher Scientific 4387406 SYBAR Green PCR Master Mix Thermo Fisher Scientific A25742 VeriKineTM Mouse IFN-a detection ELISA Kit PBL 42120-1 Mouse IFN-b Quantikine ELISA Kit RSD MIFNB0 LEGEND MAXTM Mouse IFN-g ELISA Kit Biolegend 430807 Mouse IL-28 ELISA Kit abcam ab100708 LEGEND MAXTM Mouse IL-6 ELISA Kit Biolegend 431307 LEGEND MAXTM Mouse TNF-a ELISA Kit Biolegend 430907 Human IL-29 (IFN-l1) ELISA Kit Biolegend 446307 Human IL-28A (IFN-l2) ELISA Kit RayBiotech ELH-IL28A-1 Human IL-28B/IFN-lambda 3 Quantikine ELISA Kit R&D Systems D28B00 Human Free Fatty Acid Receptor 4 (FFAR4) ELISA Kit CLOUD-CLONE SEG697HU Deposited data LC-MS/MS data MetaboLights https://www.ebi.ac.uk/metabolights/ reviewer18cf2487-8bc9-4b84-b575314f8fc149d5 Experimental models: Organisms/strains Mouse: BALB/c Charles River Laboratories Japan, Inc. N/A Mouse: C57BL/6J Charles River Laboratories Japan, Inc. N/A Mouse: Irf1 / mice The Jackson Laboratory JAX 002762 Mouse: Irf7 / mice The RIKEN BioResource Research Center RBRC01420 Human wild-type A549 cell line abcam ab255450 Human IRF-1 knockout A549 cell line abcam ab267042 Human IRF-7 knockout A549 cell line abcam ab267210 MDCK cell line Yoshihiro Kawaoka、 N/A Oligonucleotides See Table S1 for primers N/A N/A Software and algorithms Prism v9.0 GraphPad Software https://www.graphpad.com/scientific- software/prism/ FlowJo v10.07 TreeStar Inc https://www.flowjo.com/ Xcalibur 4.1 Thermo Fisher Scientific https://www.thermofisher.com/jp/ja/home/ industrial/mass-spectrometry/liquidchromatography-mass-spectrometrylc-ms/lc-ms-software/lc-ms-dataacquisition-software/xcalibur-dataacquisition-interpretation-software.html (Continued on next page) e2 Cell Reports 41, 111755, December 13, 2022 .. REAGENT or RESOURCE SOURCE IDENTIFIER Compound Discoverer3.1.1.12 Thermo Fisher Scientific https://www.thermofisher.com/jp/ja/ home/industrial/mass-spectrometry/ liquid-chromatography-massspectrometry-lc-ms/lc-ms-software/ multi-omics-data-analysis/compounddiscoverer-software.html Other TissueLyser II QIAGEN 85300 Stainless beads, 3mm TAITEC 0068218-000 100-mm cell strainer PLS 43-50100-03 FACSCantTM II BD Biosciences N/A Step One Plus (Real-time PCR system) Thermo Fisher Scientific N/A Liquid chromatography-tandem mass spectrometry (LC-MS/MS) Thermo Fisher Scientific N/A FACSCantTM II BD Biosciences N/A Freeze dryer EYELA FDU-2200 Centrifugal evaporator EYELA CVE-3110 Cooling trap device EYELA UT-2000 Diaphragm vacuum pomp EYELA NVP-2100 Vacuum pomp EYELA GCD-136XN Ball mill Retsxh MM 400 Zirconia ball NIKKATO CORPORATION YTZ-0.3 Centrifuge HITACHI CF16RN Vortex mixer Scientific Industries SI-0286 Methanol FUJIFILM Wako Pure Corporation 134-14523 Acetonitrile FUJIFILM Wako Pure Corporation 018-19853 BD Microtainer SST Tubes BD Biosciences 365967 SpectraMax iD5 Molecular Devices N/A

    Knock-Out:

    Article Title: Clostridium butyricum-induced ω-3 fatty acid 18-HEPE elicits anti-influenza virus pneumonia effects through interferon-λ upregulation.
    Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies IL-28A/IFN-lambda 2 anti-Mouse Monoclonal Ab (625,616) RSD MAB4635; RRID: AB_10718823 IL-28B/IFN-lambda 3 anti-mouse Monoclonal Ab (244,710) RSD MAB1789; RRID: AB_2233689 FITC-labeled anti-CD4 Ab (RM4-5) BD Biosciences 561,835; RRID: AB_394582 Per-CP-labeled anti-CD3 Ab (145-2C11) BD Biosciences 561,089; RRID: AB_394599 PE-labeled anti-CD8 Ab (53–6.7) BD Biosciences 561,095; RRID: AB_394571 Rat IgG2b Isotype Control antibody (LTF-2) Thermo Fisher Scientific 02-9288; RRID: AB_2532966 APC-labeled anti-CD326 (Ep-CAM) Ab (G8.8) Biolegend 118,213; RRID: AB_1134105 PB-labeled anti-CD45 Ab (30-F11) Biolegend 103,128; RRID: AB_493715 FITC-labeled anti-CD11c Ab (N418) Biolegend 117,305; RRID: AB_313774 PerCP anti-I-A/I-E (MHC II) Ab (M5/114.15.2) Biolegend 107,623; RRID: AB_893586 Bacterial and viral strains Bacterium: Clostridium butyricum MIYAIRI 588 MIYARISAN Pharmaceutical Co. N/A Virus: Influenza virus (A/Aichi/2/68) (H3N2) Yoshihiro Kawaoka N/A Chemicals, peptides, and recombinant proteins Penicillin-Streptomycin-Amphotericin B Suspension (1003) Wako 161-23181 MEM (103) gibco 11430-030 MEM Amino Acids (503) gibco 11130-051 MEM Vitamin Solution (1003) gibco 11120-052 Distilled water gibco 15230204 Newborn Calf Serum, heat inactivated gibco 26010066 0.25% Trypsin (13) gibco 15050065 Sodium bicarbonate solution (7.5% NaHCO3) Sigma S8761-100mL BSA Solution (7.5%) Sigma A8412-100ML L-Glutamine Solution (50x) Sigma G7513-100ML 0.5%-Trypan Blue Stain Solution Nacalai tesque 29853-34 Crystal Violet Nacalai tesque 09803-62 F-12K Medium ATCC ATCC 30-2004 Collagenase, type IV Worthington Collagenase LS004209 Recombinant DNase I (RNase-free) Takara 2270A RPMI 1640 Thermo Fisher Scientific 11875-085 HBSS Thermo Fisher Scientific 14025-76 EDTA Sigma E5134-50g Percoll GE Healthcare 17-0891-02 Formalin solution neutral buffered, 10% SIGMA HT501128-4L USDA-Grade Certified Fatal Bovine Serum [FBS] Cosmo bio 04-001-1A Isoflurane Pfizer 114-133403 (±)18-HEPE CAY 32840 AH7614 CAY 17713 GW1100 CEM CS-0280 Ionomycin Sigma I9657 Myristic acid Sigma M312 (Continued on next page) Cell Reports 41, 111755, December 13, 2022 e1 .. REAGENT or RESOURCE SOURCE IDENTIFIER Linoleic acid Sigma L1376 Oleic acid Sigma O1008 TUG-891 CAY 17035 FITC-dextran Sigma FD4-1G Critical commercial assays NucleoSpin RNA (Total RNA isolation Kit) MACHEREY-NAGEL 740955.50 Fixation/Permeablization Kit BD Biosciences 554714 High-Capacity RNA-to-cDNA Kit Thermo Fisher Scientific 4387406 SYBAR Green PCR Master Mix Thermo Fisher Scientific A25742 VeriKineTM Mouse IFN-a detection ELISA Kit PBL 42120-1 Mouse IFN-b Quantikine ELISA Kit RSD MIFNB0 LEGEND MAXTM Mouse IFN-g ELISA Kit Biolegend 430807 Mouse IL-28 ELISA Kit abcam ab100708 LEGEND MAXTM Mouse IL-6 ELISA Kit Biolegend 431307 LEGEND MAXTM Mouse TNF-a ELISA Kit Biolegend 430907 Human IL-29 (IFN-l1) ELISA Kit Biolegend 446307 Human IL-28A (IFN-l2) ELISA Kit RayBiotech ELH-IL28A-1 Human IL-28B/IFN-lambda 3 Quantikine ELISA Kit R&D Systems D28B00 Human Free Fatty Acid Receptor 4 (FFAR4) ELISA Kit CLOUD-CLONE SEG697HU Deposited data LC-MS/MS data MetaboLights https://www.ebi.ac.uk/metabolights/ reviewer18cf2487-8bc9-4b84-b575314f8fc149d5 Experimental models: Organisms/strains Mouse: BALB/c Charles River Laboratories Japan, Inc. N/A Mouse: C57BL/6J Charles River Laboratories Japan, Inc. N/A Mouse: Irf1 / mice The Jackson Laboratory JAX 002762 Mouse: Irf7 / mice The RIKEN BioResource Research Center RBRC01420 Human wild-type A549 cell line abcam ab255450 Human IRF-1 knockout A549 cell line abcam ab267042 Human IRF-7 knockout A549 cell line abcam ab267210 MDCK cell line Yoshihiro Kawaoka、 N/A Oligonucleotides See Table S1 for primers N/A N/A Software and algorithms Prism v9.0 GraphPad Software https://www.graphpad.com/scientific- software/prism/ FlowJo v10.07 TreeStar Inc https://www.flowjo.com/ Xcalibur 4.1 Thermo Fisher Scientific https://www.thermofisher.com/jp/ja/home/ industrial/mass-spectrometry/liquidchromatography-mass-spectrometrylc-ms/lc-ms-software/lc-ms-dataacquisition-software/xcalibur-dataacquisition-interpretation-software.html (Continued on next page) e2 Cell Reports 41, 111755, December 13, 2022 .. REAGENT or RESOURCE SOURCE IDENTIFIER Compound Discoverer3.1.1.12 Thermo Fisher Scientific https://www.thermofisher.com/jp/ja/ home/industrial/mass-spectrometry/ liquid-chromatography-massspectrometry-lc-ms/lc-ms-software/ multi-omics-data-analysis/compounddiscoverer-software.html Other TissueLyser II QIAGEN 85300 Stainless beads, 3mm TAITEC 0068218-000 100-mm cell strainer PLS 43-50100-03 FACSCantTM II BD Biosciences N/A Step One Plus (Real-time PCR system) Thermo Fisher Scientific N/A Liquid chromatography-tandem mass spectrometry (LC-MS/MS) Thermo Fisher Scientific N/A FACSCantTM II BD Biosciences N/A Freeze dryer EYELA FDU-2200 Centrifugal evaporator EYELA CVE-3110 Cooling trap device EYELA UT-2000 Diaphragm vacuum pomp EYELA NVP-2100 Vacuum pomp EYELA GCD-136XN Ball mill Retsxh MM 400 Zirconia ball NIKKATO CORPORATION YTZ-0.3 Centrifuge HITACHI CF16RN Vortex mixer Scientific Industries SI-0286 Methanol FUJIFILM Wako Pure Corporation 134-14523 Acetonitrile FUJIFILM Wako Pure Corporation 018-19853 BD Microtainer SST Tubes BD Biosciences 365967 SpectraMax iD5 Molecular Devices N/A

    Software:

    Article Title: Clostridium butyricum-induced ω-3 fatty acid 18-HEPE elicits anti-influenza virus pneumonia effects through interferon-λ upregulation.
    Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies IL-28A/IFN-lambda 2 anti-Mouse Monoclonal Ab (625,616) RSD MAB4635; RRID: AB_10718823 IL-28B/IFN-lambda 3 anti-mouse Monoclonal Ab (244,710) RSD MAB1789; RRID: AB_2233689 FITC-labeled anti-CD4 Ab (RM4-5) BD Biosciences 561,835; RRID: AB_394582 Per-CP-labeled anti-CD3 Ab (145-2C11) BD Biosciences 561,089; RRID: AB_394599 PE-labeled anti-CD8 Ab (53–6.7) BD Biosciences 561,095; RRID: AB_394571 Rat IgG2b Isotype Control antibody (LTF-2) Thermo Fisher Scientific 02-9288; RRID: AB_2532966 APC-labeled anti-CD326 (Ep-CAM) Ab (G8.8) Biolegend 118,213; RRID: AB_1134105 PB-labeled anti-CD45 Ab (30-F11) Biolegend 103,128; RRID: AB_493715 FITC-labeled anti-CD11c Ab (N418) Biolegend 117,305; RRID: AB_313774 PerCP anti-I-A/I-E (MHC II) Ab (M5/114.15.2) Biolegend 107,623; RRID: AB_893586 Bacterial and viral strains Bacterium: Clostridium butyricum MIYAIRI 588 MIYARISAN Pharmaceutical Co. N/A Virus: Influenza virus (A/Aichi/2/68) (H3N2) Yoshihiro Kawaoka N/A Chemicals, peptides, and recombinant proteins Penicillin-Streptomycin-Amphotericin B Suspension (1003) Wako 161-23181 MEM (103) gibco 11430-030 MEM Amino Acids (503) gibco 11130-051 MEM Vitamin Solution (1003) gibco 11120-052 Distilled water gibco 15230204 Newborn Calf Serum, heat inactivated gibco 26010066 0.25% Trypsin (13) gibco 15050065 Sodium bicarbonate solution (7.5% NaHCO3) Sigma S8761-100mL BSA Solution (7.5%) Sigma A8412-100ML L-Glutamine Solution (50x) Sigma G7513-100ML 0.5%-Trypan Blue Stain Solution Nacalai tesque 29853-34 Crystal Violet Nacalai tesque 09803-62 F-12K Medium ATCC ATCC 30-2004 Collagenase, type IV Worthington Collagenase LS004209 Recombinant DNase I (RNase-free) Takara 2270A RPMI 1640 Thermo Fisher Scientific 11875-085 HBSS Thermo Fisher Scientific 14025-76 EDTA Sigma E5134-50g Percoll GE Healthcare 17-0891-02 Formalin solution neutral buffered, 10% SIGMA HT501128-4L USDA-Grade Certified Fatal Bovine Serum [FBS] Cosmo bio 04-001-1A Isoflurane Pfizer 114-133403 (±)18-HEPE CAY 32840 AH7614 CAY 17713 GW1100 CEM CS-0280 Ionomycin Sigma I9657 Myristic acid Sigma M312 (Continued on next page) Cell Reports 41, 111755, December 13, 2022 e1 .. REAGENT or RESOURCE SOURCE IDENTIFIER Linoleic acid Sigma L1376 Oleic acid Sigma O1008 TUG-891 CAY 17035 FITC-dextran Sigma FD4-1G Critical commercial assays NucleoSpin RNA (Total RNA isolation Kit) MACHEREY-NAGEL 740955.50 Fixation/Permeablization Kit BD Biosciences 554714 High-Capacity RNA-to-cDNA Kit Thermo Fisher Scientific 4387406 SYBAR Green PCR Master Mix Thermo Fisher Scientific A25742 VeriKineTM Mouse IFN-a detection ELISA Kit PBL 42120-1 Mouse IFN-b Quantikine ELISA Kit RSD MIFNB0 LEGEND MAXTM Mouse IFN-g ELISA Kit Biolegend 430807 Mouse IL-28 ELISA Kit abcam ab100708 LEGEND MAXTM Mouse IL-6 ELISA Kit Biolegend 431307 LEGEND MAXTM Mouse TNF-a ELISA Kit Biolegend 430907 Human IL-29 (IFN-l1) ELISA Kit Biolegend 446307 Human IL-28A (IFN-l2) ELISA Kit RayBiotech ELH-IL28A-1 Human IL-28B/IFN-lambda 3 Quantikine ELISA Kit R&D Systems D28B00 Human Free Fatty Acid Receptor 4 (FFAR4) ELISA Kit CLOUD-CLONE SEG697HU Deposited data LC-MS/MS data MetaboLights https://www.ebi.ac.uk/metabolights/ reviewer18cf2487-8bc9-4b84-b575314f8fc149d5 Experimental models: Organisms/strains Mouse: BALB/c Charles River Laboratories Japan, Inc. N/A Mouse: C57BL/6J Charles River Laboratories Japan, Inc. N/A Mouse: Irf1 / mice The Jackson Laboratory JAX 002762 Mouse: Irf7 / mice The RIKEN BioResource Research Center RBRC01420 Human wild-type A549 cell line abcam ab255450 Human IRF-1 knockout A549 cell line abcam ab267042 Human IRF-7 knockout A549 cell line abcam ab267210 MDCK cell line Yoshihiro Kawaoka、 N/A Oligonucleotides See Table S1 for primers N/A N/A Software and algorithms Prism v9.0 GraphPad Software https://www.graphpad.com/scientific- software/prism/ FlowJo v10.07 TreeStar Inc https://www.flowjo.com/ Xcalibur 4.1 Thermo Fisher Scientific https://www.thermofisher.com/jp/ja/home/ industrial/mass-spectrometry/liquidchromatography-mass-spectrometrylc-ms/lc-ms-software/lc-ms-dataacquisition-software/xcalibur-dataacquisition-interpretation-software.html (Continued on next page) e2 Cell Reports 41, 111755, December 13, 2022 .. REAGENT or RESOURCE SOURCE IDENTIFIER Compound Discoverer3.1.1.12 Thermo Fisher Scientific https://www.thermofisher.com/jp/ja/ home/industrial/mass-spectrometry/ liquid-chromatography-massspectrometry-lc-ms/lc-ms-software/ multi-omics-data-analysis/compounddiscoverer-software.html Other TissueLyser II QIAGEN 85300 Stainless beads, 3mm TAITEC 0068218-000 100-mm cell strainer PLS 43-50100-03 FACSCantTM II BD Biosciences N/A Step One Plus (Real-time PCR system) Thermo Fisher Scientific N/A Liquid chromatography-tandem mass spectrometry (LC-MS/MS) Thermo Fisher Scientific N/A FACSCantTM II BD Biosciences N/A Freeze dryer EYELA FDU-2200 Centrifugal evaporator EYELA CVE-3110 Cooling trap device EYELA UT-2000 Diaphragm vacuum pomp EYELA NVP-2100 Vacuum pomp EYELA GCD-136XN Ball mill Retsxh MM 400 Zirconia ball NIKKATO CORPORATION YTZ-0.3 Centrifuge HITACHI CF16RN Vortex mixer Scientific Industries SI-0286 Methanol FUJIFILM Wako Pure Corporation 134-14523 Acetonitrile FUJIFILM Wako Pure Corporation 018-19853 BD Microtainer SST Tubes BD Biosciences 365967 SpectraMax iD5 Molecular Devices N/A

    other:

    Article Title: TRIM29 controls enteric RNA virus-induced intestinal inflammation by targeting NLRP6 and NLRP9b signaling pathways.
    Article Snippet: Infections by enteric virus and intestinal inflammation are recognized as a leading cause of deadly gastroenteritis, and NLRP6 and NLRP9b signaling control these infection and inflammation.. However, the regulatory mechanisms of the NLRP6 and NLRP9b signaling in enteric viral infection remain unexplored.. In this study, we found that the E3 ligase TRIM29 suppressed type III interferon (IFN-λ) and interleukin-18 (IL-18) production by intestinal epithelial cells (IECs) when exposed to polyinosinic:polycytidylic acid (poly I:C) and enteric RNA viruses.



    Similar Products

    94
    PBL Assay diy human ifn lambda 2 3
    Diy Human Ifn Lambda 2 3, supplied by PBL Assay, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+lambda+elisa+kit/DIY+Human+IFN-Lambda+2-3+(IL-28A-B)+ELISA+Kit/pm41525418-453-25-31
    Average 94 stars, based on 1 article reviews
    diy human ifn lambda 2 3 - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    PBL Assay elisa kit
    Elisa Kit, supplied by PBL Assay, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+lambda+elisa+kit/DIY+Human+IFN-Lambda+1-2-3+(IL-29-28A-28B)+ELISA+Kit/pm42735312-364-6-8
    Average 94 stars, based on 1 article reviews
    elisa kit - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    PBL Assay elisa
    Elisa, supplied by PBL Assay, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+lambda+elisa+kit/DIY+Human+IFN-Lambda+1-2-3+(IL-29-28A-28B)+ELISA+Kit/bio_rxiv__64898__2026__08__27__747488-85-4-8
    Average 94 stars, based on 1 article reviews
    elisa - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    93
    Fortis Life Sciences intracellular lambda light chain levels
    Intracellular Lambda Light Chain Levels, supplied by Fortis Life Sciences, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+lambda+elisa+kit/Human+Lambda+ELISA+Kit/pm41861438-243-18-30
    Average 93 stars, based on 1 article reviews
    intracellular lambda light chain levels - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    94
    PBL Assay type iii ifn elisa
    (A) Model for relationship between LATS1/2, YAP, and P53 in inhibiting cell proliferation. (B) Subconfluent BCi were treated with IFNλ1 or IFNβ for 24 hours. Fold change in cell count from 0 to 24 hours is shown, with dashed line at 1 representing starting cell number. Graph shows mean and SEM of four replicates per condition, with means compared using Ordinary One-Way ANOVA test. (C) BCi were grown to confluence, followed by IFNλ1 or IFNβ pretreatment and wounding with a standardized linear scratch (600 µm). Fraction of wound area remaining was quantified over time to calculate AUC. Mean and SEM of four replicates per condition are shown, with AUCs compared using Ordinary One-Way ANOVA test. (D) siCtrl and siLATS1/2-transfected BCi were treated with IFNλ1 or IFNβ for 24 hours. Fold change in cell count from 0 to 24 hours is shown, with dashed line at 1 representing starting cell number. Graph shows mean and SEM of four replicates per condition, with means compared using Ordinary One-Way ANOVA test. (E–G) BCi were transduced with an empty vector (EV) or YAP5SA. (E) western blot on EV and YAP5SA BCi lysates for Flag-tag. (F) EV and YAP5SA BCi were grown to confluence, followed by IFNλ1 or IFNβ treatment and wounding with a standardized linear scratch (600 µm). Fraction of wound area remaining was quantified. Graph shows mean and SEM of <t>three</t> replicates per condition, with means compared using Ordinary One-Way ANOVA test. (G) Subconfluent EV and YAP5SA BCi were treated with IFNλ1 or IFNβ for 24 hours. Fold change in cell count from 0 to 24 hours is shown, with dashed line at 1 representing starting cell number. Graphs show mean and SEM of four replicates per condition, with means compared using Ordinary One-Way ANOVA test. (H) western blot for p53 on cell lysates of siCtrl and siTP53-transfected HBEC four days after transfection. (I) siCtrl and siTP53 BCi were treated with IFNλ1 or IFNβ for 24 hours. Fold change in cell count from 0 to 24 hours is shown, with dashed line at 1 representing starting cell number. Graphs show mean and SEM of three replicates per condition, with means compared using Ordinary One-Way ANOVA test. (J) siCtrl and siTP53 HBEC were grown to confluence, followed by IFNλ1 (red) or IFNβ (blue) treatment and wounding with a standardized linear scratch (600 µm). Fraction of wound area remaining was quantified over time to calculate AUC. Graph shows mean and SEM of four replicates per condition, with AUCs compared using Ordinary One-Way ANOVA test. The data underlying this figure can be found in and .
    Type Iii Ifn Elisa, supplied by PBL Assay, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+lambda+elisa+kit/DIY+Human+IFN-Lambda+1-2-3+(IL-29-28A-28B)+ELISA+Kit/pmc12863674-292-33-37
    Average 94 stars, based on 1 article reviews
    type iii ifn elisa - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    94
    R&D Systems duoset elisa kits
    (A) Model for relationship between LATS1/2, YAP, and P53 in inhibiting cell proliferation. (B) Subconfluent BCi were treated with IFNλ1 or IFNβ for 24 hours. Fold change in cell count from 0 to 24 hours is shown, with dashed line at 1 representing starting cell number. Graph shows mean and SEM of four replicates per condition, with means compared using Ordinary One-Way ANOVA test. (C) BCi were grown to confluence, followed by IFNλ1 or IFNβ pretreatment and wounding with a standardized linear scratch (600 µm). Fraction of wound area remaining was quantified over time to calculate AUC. Mean and SEM of four replicates per condition are shown, with AUCs compared using Ordinary One-Way ANOVA test. (D) siCtrl and siLATS1/2-transfected BCi were treated with IFNλ1 or IFNβ for 24 hours. Fold change in cell count from 0 to 24 hours is shown, with dashed line at 1 representing starting cell number. Graph shows mean and SEM of four replicates per condition, with means compared using Ordinary One-Way ANOVA test. (E–G) BCi were transduced with an empty vector (EV) or YAP5SA. (E) western blot on EV and YAP5SA BCi lysates for Flag-tag. (F) EV and YAP5SA BCi were grown to confluence, followed by IFNλ1 or IFNβ treatment and wounding with a standardized linear scratch (600 µm). Fraction of wound area remaining was quantified. Graph shows mean and SEM of <t>three</t> replicates per condition, with means compared using Ordinary One-Way ANOVA test. (G) Subconfluent EV and YAP5SA BCi were treated with IFNλ1 or IFNβ for 24 hours. Fold change in cell count from 0 to 24 hours is shown, with dashed line at 1 representing starting cell number. Graphs show mean and SEM of four replicates per condition, with means compared using Ordinary One-Way ANOVA test. (H) western blot for p53 on cell lysates of siCtrl and siTP53-transfected HBEC four days after transfection. (I) siCtrl and siTP53 BCi were treated with IFNλ1 or IFNβ for 24 hours. Fold change in cell count from 0 to 24 hours is shown, with dashed line at 1 representing starting cell number. Graphs show mean and SEM of three replicates per condition, with means compared using Ordinary One-Way ANOVA test. (J) siCtrl and siTP53 HBEC were grown to confluence, followed by IFNλ1 (red) or IFNβ (blue) treatment and wounding with a standardized linear scratch (600 µm). Fraction of wound area remaining was quantified over time to calculate AUC. Graph shows mean and SEM of four replicates per condition, with AUCs compared using Ordinary One-Way ANOVA test. The data underlying this figure can be found in and .
    Duoset Elisa Kits, supplied by R&D Systems, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+lambda+elisa+kit/Human+IL-28B%2FIFN-lambda+3+DuoSet+ELISA/pm41525418-431-24-27
    Average 94 stars, based on 1 article reviews
    duoset elisa kits - by Bioz Stars, 2026-11
    94/100 stars
      Buy from Supplier

    93
    Fortis Life Sciences human lambda light chain
    (A) Model for relationship between LATS1/2, YAP, and P53 in inhibiting cell proliferation. (B) Subconfluent BCi were treated with IFNλ1 or IFNβ for 24 hours. Fold change in cell count from 0 to 24 hours is shown, with dashed line at 1 representing starting cell number. Graph shows mean and SEM of four replicates per condition, with means compared using Ordinary One-Way ANOVA test. (C) BCi were grown to confluence, followed by IFNλ1 or IFNβ pretreatment and wounding with a standardized linear scratch (600 µm). Fraction of wound area remaining was quantified over time to calculate AUC. Mean and SEM of four replicates per condition are shown, with AUCs compared using Ordinary One-Way ANOVA test. (D) siCtrl and siLATS1/2-transfected BCi were treated with IFNλ1 or IFNβ for 24 hours. Fold change in cell count from 0 to 24 hours is shown, with dashed line at 1 representing starting cell number. Graph shows mean and SEM of four replicates per condition, with means compared using Ordinary One-Way ANOVA test. (E–G) BCi were transduced with an empty vector (EV) or YAP5SA. (E) western blot on EV and YAP5SA BCi lysates for Flag-tag. (F) EV and YAP5SA BCi were grown to confluence, followed by IFNλ1 or IFNβ treatment and wounding with a standardized linear scratch (600 µm). Fraction of wound area remaining was quantified. Graph shows mean and SEM of <t>three</t> replicates per condition, with means compared using Ordinary One-Way ANOVA test. (G) Subconfluent EV and YAP5SA BCi were treated with IFNλ1 or IFNβ for 24 hours. Fold change in cell count from 0 to 24 hours is shown, with dashed line at 1 representing starting cell number. Graphs show mean and SEM of four replicates per condition, with means compared using Ordinary One-Way ANOVA test. (H) western blot for p53 on cell lysates of siCtrl and siTP53-transfected HBEC four days after transfection. (I) siCtrl and siTP53 BCi were treated with IFNλ1 or IFNβ for 24 hours. Fold change in cell count from 0 to 24 hours is shown, with dashed line at 1 representing starting cell number. Graphs show mean and SEM of three replicates per condition, with means compared using Ordinary One-Way ANOVA test. (J) siCtrl and siTP53 HBEC were grown to confluence, followed by IFNλ1 (red) or IFNβ (blue) treatment and wounding with a standardized linear scratch (600 µm). Fraction of wound area remaining was quantified over time to calculate AUC. Graph shows mean and SEM of four replicates per condition, with AUCs compared using Ordinary One-Way ANOVA test. The data underlying this figure can be found in and .
    Human Lambda Light Chain, supplied by Fortis Life Sciences, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+lambda+elisa+kit/Human+Lambda+ELISA+Kit/pm41486357-101-16-20
    Average 93 stars, based on 1 article reviews
    human lambda light chain - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    93
    Bethyl human lambda light chain
    (A) Model for relationship between LATS1/2, YAP, and P53 in inhibiting cell proliferation. (B) Subconfluent BCi were treated with IFNλ1 or IFNβ for 24 hours. Fold change in cell count from 0 to 24 hours is shown, with dashed line at 1 representing starting cell number. Graph shows mean and SEM of four replicates per condition, with means compared using Ordinary One-Way ANOVA test. (C) BCi were grown to confluence, followed by IFNλ1 or IFNβ pretreatment and wounding with a standardized linear scratch (600 µm). Fraction of wound area remaining was quantified over time to calculate AUC. Mean and SEM of four replicates per condition are shown, with AUCs compared using Ordinary One-Way ANOVA test. (D) siCtrl and siLATS1/2-transfected BCi were treated with IFNλ1 or IFNβ for 24 hours. Fold change in cell count from 0 to 24 hours is shown, with dashed line at 1 representing starting cell number. Graph shows mean and SEM of four replicates per condition, with means compared using Ordinary One-Way ANOVA test. (E–G) BCi were transduced with an empty vector (EV) or YAP5SA. (E) western blot on EV and YAP5SA BCi lysates for Flag-tag. (F) EV and YAP5SA BCi were grown to confluence, followed by IFNλ1 or IFNβ treatment and wounding with a standardized linear scratch (600 µm). Fraction of wound area remaining was quantified. Graph shows mean and SEM of <t>three</t> replicates per condition, with means compared using Ordinary One-Way ANOVA test. (G) Subconfluent EV and YAP5SA BCi were treated with IFNλ1 or IFNβ for 24 hours. Fold change in cell count from 0 to 24 hours is shown, with dashed line at 1 representing starting cell number. Graphs show mean and SEM of four replicates per condition, with means compared using Ordinary One-Way ANOVA test. (H) western blot for p53 on cell lysates of siCtrl and siTP53-transfected HBEC four days after transfection. (I) siCtrl and siTP53 BCi were treated with IFNλ1 or IFNβ for 24 hours. Fold change in cell count from 0 to 24 hours is shown, with dashed line at 1 representing starting cell number. Graphs show mean and SEM of three replicates per condition, with means compared using Ordinary One-Way ANOVA test. (J) siCtrl and siTP53 HBEC were grown to confluence, followed by IFNλ1 (red) or IFNβ (blue) treatment and wounding with a standardized linear scratch (600 µm). Fraction of wound area remaining was quantified over time to calculate AUC. Graph shows mean and SEM of four replicates per condition, with AUCs compared using Ordinary One-Way ANOVA test. The data underlying this figure can be found in and .
    Human Lambda Light Chain, supplied by Bethyl, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+lambda+elisa+kit/Human+Lambda+ELISA+Kit/pmc12870532-72-16-20
    Average 93 stars, based on 1 article reviews
    human lambda light chain - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    93
    RayBiotech inc human il 28b ifn lambda 3 elisa kit
    (A) Model for relationship between LATS1/2, YAP, and P53 in inhibiting cell proliferation. (B) Subconfluent BCi were treated with IFNλ1 or IFNβ for 24 hours. Fold change in cell count from 0 to 24 hours is shown, with dashed line at 1 representing starting cell number. Graph shows mean and SEM of four replicates per condition, with means compared using Ordinary One-Way ANOVA test. (C) BCi were grown to confluence, followed by IFNλ1 or IFNβ pretreatment and wounding with a standardized linear scratch (600 µm). Fraction of wound area remaining was quantified over time to calculate AUC. Mean and SEM of four replicates per condition are shown, with AUCs compared using Ordinary One-Way ANOVA test. (D) siCtrl and siLATS1/2-transfected BCi were treated with IFNλ1 or IFNβ for 24 hours. Fold change in cell count from 0 to 24 hours is shown, with dashed line at 1 representing starting cell number. Graph shows mean and SEM of four replicates per condition, with means compared using Ordinary One-Way ANOVA test. (E–G) BCi were transduced with an empty vector (EV) or YAP5SA. (E) western blot on EV and YAP5SA BCi lysates for Flag-tag. (F) EV and YAP5SA BCi were grown to confluence, followed by IFNλ1 or IFNβ treatment and wounding with a standardized linear scratch (600 µm). Fraction of wound area remaining was quantified. Graph shows mean and SEM of <t>three</t> replicates per condition, with means compared using Ordinary One-Way ANOVA test. (G) Subconfluent EV and YAP5SA BCi were treated with IFNλ1 or IFNβ for 24 hours. Fold change in cell count from 0 to 24 hours is shown, with dashed line at 1 representing starting cell number. Graphs show mean and SEM of four replicates per condition, with means compared using Ordinary One-Way ANOVA test. (H) western blot for p53 on cell lysates of siCtrl and siTP53-transfected HBEC four days after transfection. (I) siCtrl and siTP53 BCi were treated with IFNλ1 or IFNβ for 24 hours. Fold change in cell count from 0 to 24 hours is shown, with dashed line at 1 representing starting cell number. Graphs show mean and SEM of three replicates per condition, with means compared using Ordinary One-Way ANOVA test. (J) siCtrl and siTP53 HBEC were grown to confluence, followed by IFNλ1 (red) or IFNβ (blue) treatment and wounding with a standardized linear scratch (600 µm). Fraction of wound area remaining was quantified over time to calculate AUC. Graph shows mean and SEM of four replicates per condition, with AUCs compared using Ordinary One-Way ANOVA test. The data underlying this figure can be found in and .
    Human Il 28b Ifn Lambda 3 Elisa Kit, supplied by RayBiotech inc, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/human+lambda+elisa+kit/Human+IL-29+ELISA/bio_rxiv__64898__2025__12__17__694833-173-6-11
    Average 93 stars, based on 1 article reviews
    human il 28b ifn lambda 3 elisa kit - by Bioz Stars, 2026-11
    93/100 stars
      Buy from Supplier

    Image Search Results


    (A) Model for relationship between LATS1/2, YAP, and P53 in inhibiting cell proliferation. (B) Subconfluent BCi were treated with IFNλ1 or IFNβ for 24 hours. Fold change in cell count from 0 to 24 hours is shown, with dashed line at 1 representing starting cell number. Graph shows mean and SEM of four replicates per condition, with means compared using Ordinary One-Way ANOVA test. (C) BCi were grown to confluence, followed by IFNλ1 or IFNβ pretreatment and wounding with a standardized linear scratch (600 µm). Fraction of wound area remaining was quantified over time to calculate AUC. Mean and SEM of four replicates per condition are shown, with AUCs compared using Ordinary One-Way ANOVA test. (D) siCtrl and siLATS1/2-transfected BCi were treated with IFNλ1 or IFNβ for 24 hours. Fold change in cell count from 0 to 24 hours is shown, with dashed line at 1 representing starting cell number. Graph shows mean and SEM of four replicates per condition, with means compared using Ordinary One-Way ANOVA test. (E–G) BCi were transduced with an empty vector (EV) or YAP5SA. (E) western blot on EV and YAP5SA BCi lysates for Flag-tag. (F) EV and YAP5SA BCi were grown to confluence, followed by IFNλ1 or IFNβ treatment and wounding with a standardized linear scratch (600 µm). Fraction of wound area remaining was quantified. Graph shows mean and SEM of three replicates per condition, with means compared using Ordinary One-Way ANOVA test. (G) Subconfluent EV and YAP5SA BCi were treated with IFNλ1 or IFNβ for 24 hours. Fold change in cell count from 0 to 24 hours is shown, with dashed line at 1 representing starting cell number. Graphs show mean and SEM of four replicates per condition, with means compared using Ordinary One-Way ANOVA test. (H) western blot for p53 on cell lysates of siCtrl and siTP53-transfected HBEC four days after transfection. (I) siCtrl and siTP53 BCi were treated with IFNλ1 or IFNβ for 24 hours. Fold change in cell count from 0 to 24 hours is shown, with dashed line at 1 representing starting cell number. Graphs show mean and SEM of three replicates per condition, with means compared using Ordinary One-Way ANOVA test. (J) siCtrl and siTP53 HBEC were grown to confluence, followed by IFNλ1 (red) or IFNβ (blue) treatment and wounding with a standardized linear scratch (600 µm). Fraction of wound area remaining was quantified over time to calculate AUC. Graph shows mean and SEM of four replicates per condition, with AUCs compared using Ordinary One-Way ANOVA test. The data underlying this figure can be found in and .

    Journal: PLOS Biology

    Article Title: Dose-dependent activation of the Hippo pathway by Type I and Type III interferons suppresses tissue repair by human bronchial epithelial cells

    doi: 10.1371/journal.pbio.3003615

    Figure Lengend Snippet: (A) Model for relationship between LATS1/2, YAP, and P53 in inhibiting cell proliferation. (B) Subconfluent BCi were treated with IFNλ1 or IFNβ for 24 hours. Fold change in cell count from 0 to 24 hours is shown, with dashed line at 1 representing starting cell number. Graph shows mean and SEM of four replicates per condition, with means compared using Ordinary One-Way ANOVA test. (C) BCi were grown to confluence, followed by IFNλ1 or IFNβ pretreatment and wounding with a standardized linear scratch (600 µm). Fraction of wound area remaining was quantified over time to calculate AUC. Mean and SEM of four replicates per condition are shown, with AUCs compared using Ordinary One-Way ANOVA test. (D) siCtrl and siLATS1/2-transfected BCi were treated with IFNλ1 or IFNβ for 24 hours. Fold change in cell count from 0 to 24 hours is shown, with dashed line at 1 representing starting cell number. Graph shows mean and SEM of four replicates per condition, with means compared using Ordinary One-Way ANOVA test. (E–G) BCi were transduced with an empty vector (EV) or YAP5SA. (E) western blot on EV and YAP5SA BCi lysates for Flag-tag. (F) EV and YAP5SA BCi were grown to confluence, followed by IFNλ1 or IFNβ treatment and wounding with a standardized linear scratch (600 µm). Fraction of wound area remaining was quantified. Graph shows mean and SEM of three replicates per condition, with means compared using Ordinary One-Way ANOVA test. (G) Subconfluent EV and YAP5SA BCi were treated with IFNλ1 or IFNβ for 24 hours. Fold change in cell count from 0 to 24 hours is shown, with dashed line at 1 representing starting cell number. Graphs show mean and SEM of four replicates per condition, with means compared using Ordinary One-Way ANOVA test. (H) western blot for p53 on cell lysates of siCtrl and siTP53-transfected HBEC four days after transfection. (I) siCtrl and siTP53 BCi were treated with IFNλ1 or IFNβ for 24 hours. Fold change in cell count from 0 to 24 hours is shown, with dashed line at 1 representing starting cell number. Graphs show mean and SEM of three replicates per condition, with means compared using Ordinary One-Way ANOVA test. (J) siCtrl and siTP53 HBEC were grown to confluence, followed by IFNλ1 (red) or IFNβ (blue) treatment and wounding with a standardized linear scratch (600 µm). Fraction of wound area remaining was quantified over time to calculate AUC. Graph shows mean and SEM of four replicates per condition, with AUCs compared using Ordinary One-Way ANOVA test. The data underlying this figure can be found in and .

    Article Snippet: Basolateral media was collected for LDH assay (Cayman Chemical #601170, as described in manufacturer’s protocol, with values calculated from standard curve of lysed cells), Type I IFN reporter assay (InvivoGen, Cat# hkb-ifnabv2), and Type III IFN ELISA (PBL Assay Science, Cat# 61840).

    Techniques: Cell Characterization, Transfection, Transduction, Plasmid Preparation, Western Blot, FLAG-tag

    (A) Type III IFN receptor signaling and targets of ruxolitinib (rux) and fludarabine (flud). (B) Subconfluent HBEC were pretreated with rux or flud prior to IFNλ1 treatment, followed by western blot on cell lysates pLATS1 Ser 909 and total LATS1. (C, D) Subconfluent HBEC were pretreated with rux or flud prior to treatment with IFNλ1 for 24 hours, followed by RNA isolation and RT-qPCR for CYR61 or BIRC5 . Graphs show mean and SEM of three replicates per condition, with means compared using Ordinary One-Way ANOVA test. (E) Confluent rux- and flud-pretreated HBEC were treated with IFNλ1 followed by wounding with a standardized linear scratch (600 µm). Fraction of wound area remaining was quantified over time to calculate AUC. Graph shows mean and SEM of four replicates per condition, with means compared using Ordinary One-Way ANOVA test. (F–L) Rux- or flud-pretreated HBEC treated with IFNλ1 were fixed four hours after wounding with a standardized linear scratch (600 µm) and stained for YAP and DAPI. (F) Number of cells with nuclear YAP within 100µm of the leading edge of the scratch were quantified for each condition. Graph shows mean and SEM of six high-power fields of view per condition, with means compared using Ordinary One-Way ANOVA test. (G–L) For low magnification images, scale bar = 100 µm. Solid white line represents scratch border. Insets represent field of view captured by dashed white box in low magnification images and show merged channel (bottom) or individual YAP (red) and DAPI (blue) channels. For insets, scale bar = 20 µm. (M–O) Subconfluent siCtrl or siJAK1 HBEC were treated with IFNλ1 (M, N) for 24 hours, followed by RNA isolation and RT-qPCR for YAP target genes, or (O) for six hours, followed by western blot on cell lysates for pLATS1 Ser 909 and total LATS1. (P) siCtrl or siJAK1 HBEC were grown to confluence, followed by IFNλ1 pretreatment and wounding with a standardized linear scratch (600 µm). Fraction of wound area remaining was quantified over time to calculate AUC. Graphs show mean and SEM of four replicates per condition, with means compared using Ordinary One-Way ANOVA test. The data underlying this figure can be found in , , and at https://doi.org/10.17632/6rvkfsy2n8.1 .

    Journal: PLOS Biology

    Article Title: Dose-dependent activation of the Hippo pathway by Type I and Type III interferons suppresses tissue repair by human bronchial epithelial cells

    doi: 10.1371/journal.pbio.3003615

    Figure Lengend Snippet: (A) Type III IFN receptor signaling and targets of ruxolitinib (rux) and fludarabine (flud). (B) Subconfluent HBEC were pretreated with rux or flud prior to IFNλ1 treatment, followed by western blot on cell lysates pLATS1 Ser 909 and total LATS1. (C, D) Subconfluent HBEC were pretreated with rux or flud prior to treatment with IFNλ1 for 24 hours, followed by RNA isolation and RT-qPCR for CYR61 or BIRC5 . Graphs show mean and SEM of three replicates per condition, with means compared using Ordinary One-Way ANOVA test. (E) Confluent rux- and flud-pretreated HBEC were treated with IFNλ1 followed by wounding with a standardized linear scratch (600 µm). Fraction of wound area remaining was quantified over time to calculate AUC. Graph shows mean and SEM of four replicates per condition, with means compared using Ordinary One-Way ANOVA test. (F–L) Rux- or flud-pretreated HBEC treated with IFNλ1 were fixed four hours after wounding with a standardized linear scratch (600 µm) and stained for YAP and DAPI. (F) Number of cells with nuclear YAP within 100µm of the leading edge of the scratch were quantified for each condition. Graph shows mean and SEM of six high-power fields of view per condition, with means compared using Ordinary One-Way ANOVA test. (G–L) For low magnification images, scale bar = 100 µm. Solid white line represents scratch border. Insets represent field of view captured by dashed white box in low magnification images and show merged channel (bottom) or individual YAP (red) and DAPI (blue) channels. For insets, scale bar = 20 µm. (M–O) Subconfluent siCtrl or siJAK1 HBEC were treated with IFNλ1 (M, N) for 24 hours, followed by RNA isolation and RT-qPCR for YAP target genes, or (O) for six hours, followed by western blot on cell lysates for pLATS1 Ser 909 and total LATS1. (P) siCtrl or siJAK1 HBEC were grown to confluence, followed by IFNλ1 pretreatment and wounding with a standardized linear scratch (600 µm). Fraction of wound area remaining was quantified over time to calculate AUC. Graphs show mean and SEM of four replicates per condition, with means compared using Ordinary One-Way ANOVA test. The data underlying this figure can be found in , , and at https://doi.org/10.17632/6rvkfsy2n8.1 .

    Article Snippet: Basolateral media was collected for LDH assay (Cayman Chemical #601170, as described in manufacturer’s protocol, with values calculated from standard curve of lysed cells), Type I IFN reporter assay (InvivoGen, Cat# hkb-ifnabv2), and Type III IFN ELISA (PBL Assay Science, Cat# 61840).

    Techniques: Western Blot, Isolation, Quantitative RT-PCR, Staining

    (A) Subconfluent HBEC were treated with IFNλ1 (red) or IFNβ (blue) for 6 hours at specified concentrations, followed by western blot on cell lysates for pLATS1 Ser 909 , total LATS1, pSTAT1 Tyr 701 , and total STAT1. Top three panels show western blot for pLATS1/LATS1/β actin and bottom three panels show separate western blot on same cell lysates for pSTAT1/STAT1/β actin. (B) Confluent HBEC were treated with IFNλ1 (red) or IFNβ (blue) followed by wounding with a standardized linear scratch (600µm). Fraction of wound area remaining was quantified over time to calculate AUC. Graph shows mean and SEM of three replicates per condition as a function of IFN concentration. AUCs at each IFN concentration were compared using Ordinary One-Way ANOVA test, with red and blue p-values representing comparison between no IFN and IFNλ1 or IFNβ treatment, respectively. (C–G) Subconfluent HBEC were treated with IFNλ1 or IFNλ2 at specified concentrations for (C) 6 or (D–G) 24 hours, followed by (C) western blot on cell lysates for pLATS1 Ser 909 , total LATS1, pSTAT1 Tyr 701 , and total STAT1, or (D–G) RNA isolation and RT-qPCR for ISGs and YAP target genes. Graphs show mean and SEM of four replicates per condition, with means compared using (D, E) Ordinary One-Way ANOVA or (F, G) Brown–Forsythe and Welch ANOVA tests. (H–N) Confluent HBEC were treated with IFNλ2 or IFNλ1 at specified concentrations prior to (H, J) wounding with a standardized linear scratch (600 µm) or (I, K–N) infection with RV or IAV. Photomicrographs show (H) remaining wound area at 0 and 24 hours after scratch and (I) cytopathic effects of viral infection with or without IFNλ2 pretreatment. For all images, scale bar = 100 µm. (J) Fraction of wound area remaining was quantified over time to calculate AUC. (K–N) RV and IAV replication by RT-qPCR and plaque assay at 72 hours post infection. Graphs show mean and SEM of four replicates per condition and were compared by (J) Ordinary One-Way ANOVA test or (K–N) Welch’s t test. The data underlying this figure can be found in and .

    Journal: PLOS Biology

    Article Title: Dose-dependent activation of the Hippo pathway by Type I and Type III interferons suppresses tissue repair by human bronchial epithelial cells

    doi: 10.1371/journal.pbio.3003615

    Figure Lengend Snippet: (A) Subconfluent HBEC were treated with IFNλ1 (red) or IFNβ (blue) for 6 hours at specified concentrations, followed by western blot on cell lysates for pLATS1 Ser 909 , total LATS1, pSTAT1 Tyr 701 , and total STAT1. Top three panels show western blot for pLATS1/LATS1/β actin and bottom three panels show separate western blot on same cell lysates for pSTAT1/STAT1/β actin. (B) Confluent HBEC were treated with IFNλ1 (red) or IFNβ (blue) followed by wounding with a standardized linear scratch (600µm). Fraction of wound area remaining was quantified over time to calculate AUC. Graph shows mean and SEM of three replicates per condition as a function of IFN concentration. AUCs at each IFN concentration were compared using Ordinary One-Way ANOVA test, with red and blue p-values representing comparison between no IFN and IFNλ1 or IFNβ treatment, respectively. (C–G) Subconfluent HBEC were treated with IFNλ1 or IFNλ2 at specified concentrations for (C) 6 or (D–G) 24 hours, followed by (C) western blot on cell lysates for pLATS1 Ser 909 , total LATS1, pSTAT1 Tyr 701 , and total STAT1, or (D–G) RNA isolation and RT-qPCR for ISGs and YAP target genes. Graphs show mean and SEM of four replicates per condition, with means compared using (D, E) Ordinary One-Way ANOVA or (F, G) Brown–Forsythe and Welch ANOVA tests. (H–N) Confluent HBEC were treated with IFNλ2 or IFNλ1 at specified concentrations prior to (H, J) wounding with a standardized linear scratch (600 µm) or (I, K–N) infection with RV or IAV. Photomicrographs show (H) remaining wound area at 0 and 24 hours after scratch and (I) cytopathic effects of viral infection with or without IFNλ2 pretreatment. For all images, scale bar = 100 µm. (J) Fraction of wound area remaining was quantified over time to calculate AUC. (K–N) RV and IAV replication by RT-qPCR and plaque assay at 72 hours post infection. Graphs show mean and SEM of four replicates per condition and were compared by (J) Ordinary One-Way ANOVA test or (K–N) Welch’s t test. The data underlying this figure can be found in and .

    Article Snippet: Basolateral media was collected for LDH assay (Cayman Chemical #601170, as described in manufacturer’s protocol, with values calculated from standard curve of lysed cells), Type I IFN reporter assay (InvivoGen, Cat# hkb-ifnabv2), and Type III IFN ELISA (PBL Assay Science, Cat# 61840).

    Techniques: Western Blot, Concentration Assay, Comparison, Isolation, Quantitative RT-PCR, Infection, Plaque Assay

    (A) Conditions that signal cell confluence lead to activation and phosphorylation of MST1/2. Active MST1/2 phosphorylate and activate LATS1/2, which then phosphorylate and inactivate YAP, reducing cell proliferation and migration. (B) Conditions that signal subconfluence to cells, such as a wound caused by an injury, results in increased YAP nuclear activity, promoting cell proliferation and migration. (C) During acute viral infection, high concentrations of Type III and/or Type I IFN receptor signaling trigger JAK-dependent, STAT1-independent phosphorylation of LATS1, leading to phosphorylation and degradation of YAP and reduced tissue repair activities mediated by YAP target genes. In rapidly proliferating cell types, active LATS1/2 also blocks repair in part via a p53-dependent mechanism. (D) During resolution of viral infection, lower concentrations of Type III and/or Type I IFN may continue to activate STAT1-mediated antiviral defenses but no longer activate LATS1/2, allowing epithelial repair to resume. (E–F) Time course of expected LATS-1 and STAT-1 phosphorylation for viral infections with different kinetics. Dotted lines indicate threshold IFN concentration required for LATS1 activation (high threshold) or STAT1 activation (lower threshold). (E) LATS1-P and STAT1-P time course expected for acute viral infection in which viral load and IFN induction peak at day 1 and then decline. (F) LATS1-P and STAT1-P time course expected for viral infection that continues to increase in viral load and IFN induction between days 1 and 5 post-infection. Made with Biorender.com.

    Journal: PLOS Biology

    Article Title: Dose-dependent activation of the Hippo pathway by Type I and Type III interferons suppresses tissue repair by human bronchial epithelial cells

    doi: 10.1371/journal.pbio.3003615

    Figure Lengend Snippet: (A) Conditions that signal cell confluence lead to activation and phosphorylation of MST1/2. Active MST1/2 phosphorylate and activate LATS1/2, which then phosphorylate and inactivate YAP, reducing cell proliferation and migration. (B) Conditions that signal subconfluence to cells, such as a wound caused by an injury, results in increased YAP nuclear activity, promoting cell proliferation and migration. (C) During acute viral infection, high concentrations of Type III and/or Type I IFN receptor signaling trigger JAK-dependent, STAT1-independent phosphorylation of LATS1, leading to phosphorylation and degradation of YAP and reduced tissue repair activities mediated by YAP target genes. In rapidly proliferating cell types, active LATS1/2 also blocks repair in part via a p53-dependent mechanism. (D) During resolution of viral infection, lower concentrations of Type III and/or Type I IFN may continue to activate STAT1-mediated antiviral defenses but no longer activate LATS1/2, allowing epithelial repair to resume. (E–F) Time course of expected LATS-1 and STAT-1 phosphorylation for viral infections with different kinetics. Dotted lines indicate threshold IFN concentration required for LATS1 activation (high threshold) or STAT1 activation (lower threshold). (E) LATS1-P and STAT1-P time course expected for acute viral infection in which viral load and IFN induction peak at day 1 and then decline. (F) LATS1-P and STAT1-P time course expected for viral infection that continues to increase in viral load and IFN induction between days 1 and 5 post-infection. Made with Biorender.com.

    Article Snippet: Basolateral media was collected for LDH assay (Cayman Chemical #601170, as described in manufacturer’s protocol, with values calculated from standard curve of lysed cells), Type I IFN reporter assay (InvivoGen, Cat# hkb-ifnabv2), and Type III IFN ELISA (PBL Assay Science, Cat# 61840).

    Techniques: Activation Assay, Phospho-proteomics, Migration, Activity Assay, Infection, Concentration Assay